effect of supplementation in treatment of diabetic hemodialysis patients

Not Applicable

Conditions: hemodialysis.
Chronic kidney disease

Registration Number: IRCT2016081811763N30

Lead Sponsor: Vice chancellor for research, Isfahan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 70

Inclusion Criteria

1- hemodialysis patients with glomerular filtration rate less than 10 or 25 ml/min with malnutrition and hypercalemy.
2- aged 45-75.
3-average blood pressure (systolic pressure 140-160 mmHg , diastolic pressure 90-100 mmHg)
4-diabetic patients according to American diabetes assossiation criteria.
Exclusion criteria: 1-unwilling to cooperate
2- hyperthyroidism and hypothyroidism
3-specific disease leading to bed.
4-malignant hypertension (systolic pressure more than 160 mmHg and diastolic pressure more than 100mmHg)

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: ELISA kit - µIU/ml.;Fasting blood sample. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: ensymatic - mg/dl.;HOMA-IR. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: calculation.;QUICKI. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: calculation.;HOMA-B. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: calculation.;HbA1C. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: calculation - percentage.

Secondary Outcome Measures

Name	Time	Method
itric oxide. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: ELISA kit.;TAC. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Spectrophotometry.;GSH. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Spectrophotometry.;HDL. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Ensymatic.;Cholestrol. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Ensymatic.;TG. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Ensymatic.;MDA. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Spectrophotometry.